Dopa

Parkinson 's disease Market Will Reflect Significant Growth Prospects During the Study Period [2018-2030], Anticipates DelveInsight

Retrieved on: 
Wednesday, April 14, 2021
Catecholamines, Aromatic L-amino acid decarboxylase inhibitor, Parkinson, L-DOPA, Aromatic L-amino acid decarboxylase, Parkinson's disease, Dopa, Chemistry, Health care, Health sciences

b'LAS VEGAS, April 14, 2021 /PRNewswire/ -- DelveInsight\'s " Parkinson\'s Disease Market " report provides a thorough comprehension of the Parkinson\'s Disease, historical and forecasted epidemiology, and the Parkinson\'s Disease market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan].

Key Points: 
  • b'LAS VEGAS, April 14, 2021 /PRNewswire/ -- DelveInsight\'s " Parkinson\'s Disease Market " report provides a thorough comprehension of the Parkinson\'s Disease, historical and forecasted epidemiology, and the Parkinson\'s Disease market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan].
  • In 2020, the US accounted for 38.36% of the total diagnosed prevalent cases of Parkinson\'s Disease in the 7MM.
  • Levodopa with a DOPA decarboxylase inhibitor is mostly a first-line treatment option for Parkinson\'s Disease .\nFor advanced Parkinson\'s Disease patients, mostly surgeries are preferred.
  • Most of the treatments are aimed at benefiting the tremor or rigidity that emerges from the disease.

Parkinson 's disease Market Will Reflect Significant Growth Prospects During the Study Period [2018-2030], Anticipates DelveInsight

Retrieved on: 
Wednesday, April 14, 2021
Catecholamines, Aromatic L-amino acid decarboxylase inhibitor, Parkinson, L-DOPA, Aromatic L-amino acid decarboxylase, Parkinson's disease, Dopa, Chemistry, Health care, Health sciences

b'LAS VEGAS, April 14, 2021 /PRNewswire/ -- DelveInsight\'s " Parkinson\'s Disease Market " report provides a thorough comprehension of the Parkinson\'s Disease, historical and forecasted epidemiology, and the Parkinson\'s Disease market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan].

Key Points: 
  • b'LAS VEGAS, April 14, 2021 /PRNewswire/ -- DelveInsight\'s " Parkinson\'s Disease Market " report provides a thorough comprehension of the Parkinson\'s Disease, historical and forecasted epidemiology, and the Parkinson\'s Disease market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan].
  • In 2020, the US accounted for 38.36% of the total diagnosed prevalent cases of Parkinson\'s Disease in the 7MM.
  • Levodopa with a DOPA decarboxylase inhibitor is mostly a first-line treatment option for Parkinson\'s Disease .\nFor advanced Parkinson\'s Disease patients, mostly surgeries are preferred.
  • Most of the treatments are aimed at benefiting the tremor or rigidity that emerges from the disease.

IRICoR, Université de Montréal, IRIC and Valence Discovery collaborate to design novel drug candidates for the treatment of levodopa-induced dyskinesia in Parkinson's disease patients

Retrieved on: 
Wednesday, March 10, 2021
Drugs, Catecholamines, Branches of biology, Parkinson's disease, Clinical medicine, Aging-associated diseases, L-DOPA, Prodrugs, Levodopa-induced dyskinesia, Dopa, Carbidopa, Gene therapy in Parkinson's disease

Parkinson's disease is a progressive neurodegenerative disease with the prevalence of one in 100 people over the age of 60, or around five million people worldwide.

Key Points: 
  • Parkinson's disease is a progressive neurodegenerative disease with the prevalence of one in 100 people over the age of 60, or around five million people worldwide.
  • Of these patients, almost all receive levodopa (also known as L-Dopa), a dopamine precursor that enables patients to reinitiate normal movement.
  • Levodopa-induced dyskinesia occurs with an average latency of around six years and affects 95% of all patients within 15 years of chronic L-Dopa treatment.
  • Valence's AI-enabled drug design platform has been extensively validated and is currently being used to identify and design drug candidates in collaboration with industry-leading partners.

Kyowa Kirin Announces Marketing Authorisation Application for Istradefylline Validated by European Medicines Agency

Retrieved on: 
Monday, January 6, 2020
Organic compounds, Medicine, Health, Istradefylline, Xanthines, Kirin, L-DOPA, Parkinson's disease, Dopa

TOKYO, Jan. 6, 2020 /PRNewswire/ -- Kyowa Kirin Co., Ltd. (TSE: 4151) President and CEO: Masashi Miyamoto, "Kyowa Kirin") today announces that its marketing authorisation application (MAA) for istradefylline (KW-6002) as an adjunctive treatment to levodopa-based regimens in adult patients with Parkinson's disease (PD) experiencing "OFF" time, has been validated by the European Medicines Agency (EMA) and is now under review.

Key Points: 
  • TOKYO, Jan. 6, 2020 /PRNewswire/ -- Kyowa Kirin Co., Ltd. (TSE: 4151) President and CEO: Masashi Miyamoto, "Kyowa Kirin") today announces that its marketing authorisation application (MAA) for istradefylline (KW-6002) as an adjunctive treatment to levodopa-based regimens in adult patients with Parkinson's disease (PD) experiencing "OFF" time, has been validated by the European Medicines Agency (EMA) and is now under review.
  • "Parkinson's disease is the fastest growing neurological disorder in the world in terms of prevalence, disability and deaths1," said Abdul Mullick, President, Kyowa Kirin International (Europe, Middle East and Africa (EMEA)).
  • Kyowa Kirin focuses on creating new values in the four therapeutic areas: nephrology, oncology, immunology/allergy and neurology.
  • Istradefylline was approved in Japan (product name: NOURIAST) in March 2013 for improving the "wearing-off" phenomenon in patients with Parkinson's disease on levodopa-containing preparations.

Kyowa Kirin Announces Marketing Authorisation Application for Istradefylline Validated by European Medicines Agency

Retrieved on: 
Monday, January 6, 2020
Organic compounds, Medicine, Health, Istradefylline, Xanthines, Kirin, L-DOPA, Parkinson's disease, Dopa

TOKYO, Jan. 6, 2020 /PRNewswire/ -- Kyowa Kirin Co., Ltd. (TSE: 4151) President and CEO: Masashi Miyamoto, "Kyowa Kirin") today announces that its marketing authorisation application (MAA) for istradefylline (KW-6002) as an adjunctive treatment to levodopa-based regimens in adult patients with Parkinson's disease (PD) experiencing "OFF" time, has been validated by the European Medicines Agency (EMA) and is now under review.

Key Points: 
  • TOKYO, Jan. 6, 2020 /PRNewswire/ -- Kyowa Kirin Co., Ltd. (TSE: 4151) President and CEO: Masashi Miyamoto, "Kyowa Kirin") today announces that its marketing authorisation application (MAA) for istradefylline (KW-6002) as an adjunctive treatment to levodopa-based regimens in adult patients with Parkinson's disease (PD) experiencing "OFF" time, has been validated by the European Medicines Agency (EMA) and is now under review.
  • "Parkinson's disease is the fastest growing neurological disorder in the world in terms of prevalence, disability and deaths1," said Abdul Mullick, President, Kyowa Kirin International (Europe, Middle East and Africa (EMEA)).
  • Kyowa Kirin focuses on creating new values in the four therapeutic areas: nephrology, oncology, immunology/allergy and neurology.
  • Istradefylline was approved in Japan (product name: NOURIAST) in March 2013 for improving the "wearing-off" phenomenon in patients with Parkinson's disease on levodopa-containing preparations.

Acorda Receives Positive CHMP Opinion for INBRIJA™ (levodopa inhalation powder)

Retrieved on: 
Friday, July 26, 2019
FDA, Clinical trials, Biotechnology, Other Health, Pharmaceutical, Health, General Health, Catecholamines, Medicine, Aromatic L-amino acid decarboxylase inhibitor, L-DOPA, Parkinson's disease, Dopa, Tyrosine hydroxylase, Health, Branches of biology, CHMP, Acorda Therapeutics, Parkinson’s and OFF Periods, INBRIJA(levodopa inhalation powder)

The European Commission (EC) will now consider the CHMP positive opinion in its decision of whether to grant marketing authorization for INBRIJA in Europe; the final EC decision is expected in the coming months.

Key Points: 
  • The European Commission (EC) will now consider the CHMP positive opinion in its decision of whether to grant marketing authorization for INBRIJA in Europe; the final EC decision is expected in the coming months.
  • Acorda is currently evaluating partnering opportunities to commercialize INBRIJA in Europe.
  • The positive CHMP decision is based on a clinical program for INBRIJA that included approximately 900 people with Parkinsons on a levodopa/dopa-decarboxylase inhibitor regimen experiencing OFF periods.
  • INBRIJA utilizes Acordas innovative ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation.

Global $5.6 Bn Parkinson's Disease Drugs Markets, 2018-2019 & 2024 - Supportive initiatives from Government and Other Organizations & Exhaustive Pipeline and Increasing Clinical Trials

Retrieved on: 
Monday, April 8, 2019
Parkinson's disease, Organ systems, Medicine, Health, RTT, Neurological disorders, Aging-associated diseases, Geriatrics, Dyskinesia, L-DOPA, Dopa, Levodopa-induced dyskinesia

DUBLIN, April 8, 2019 /PRNewswire/ -- The "Global Parkinson's Disease Drugs Market 2018-2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, April 8, 2019 /PRNewswire/ -- The "Global Parkinson's Disease Drugs Market 2018-2024" report has been added to ResearchAndMarkets.com's offering.
  • The Parkinson's Disease Foundation has stated that nearly 10 million people are suffering from this disorder globally.
  • The highest frequency of this disorder is observed in developed countries, and in the US, almost 60,000 new cases are reported annually.
  • Recently, in January 2018, Adamas Pharmaceuticals Inc. launched Gocovri for the treatment of dyskinesia in individuals with PD, who are taking levodopa.

Acorda to Present at Oppenheimer’s 29th Annual Healthcare Conference

Retrieved on: 
Wednesday, March 6, 2019
Health, Pharmaceutical, General Health, Drugs, Medicine, Catecholamines, RTT, Acorda Therapeutics, Combination drugs, Carbidopa, L-DOPA, Parkinson's disease, Dopa

Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Andrew Hindman, Acordas Chief Business Officer, will present at the Oppenheimer & Co.

Key Points: 
  • Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Andrew Hindman, Acordas Chief Business Officer, will present at the Oppenheimer & Co.
  • Annual Healthcare Conference on Tuesday, March 19 at 1:35 p.m. EST.
  • INBRIJA (levodopa inhalation powder) is approved for intermittent treatment of OFF episodes in adults with Parkinsons disease treated with carbidopa/levodopa.
  • All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking.

Acorda Announces The Lancet Neurology Publication of Phase 3 Data for INBRIJA™ (levodopa inhalation powder)

Retrieved on: 
Thursday, January 17, 2019
Health, Clinical trials, Research, Science, Medicine, Catecholamines, Chemistry, Pharmacology, RTT, Combination drugs, Parkinson's disease, Carbidopa, Hydrazines, L-DOPA, Dopa, CVT-301

INBRIJA is the first and only inhaled levodopa for intermittent treatment of OFF episodes in patients with Parkinsons disease treated with carbidopa/levodopa.

Key Points: 
  • INBRIJA is the first and only inhaled levodopa for intermittent treatment of OFF episodes in patients with Parkinsons disease treated with carbidopa/levodopa.
  • A Marketing Authorization Application (MAA) for INBRIJA was submitted to the European Medicines Agency (EMA) in March 2018 and was formally validated in May 2018.
  • Levodopa (the medicine in INBRIJA) can pass into breastmilk and it is unknown if it can harm the baby.
  • INBRIJA (levodopa inhalation powder) is approved for intermittent treatment of OFF episodes in patients with Parkinsons treated with carbidopa/levodopa.